期刊
CURRENT PHARMACEUTICAL DESIGN
卷 20, 期 32, 页码 5151-5159出版社
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/1381612819666140110120435
关键词
Depression; glutamate; NMDA receptors; GluN2B subtype; ketamine; treatment-resistant
资金
- National Natural Science Foundation of China [81171262, 81271487, 81171256]
- Minister of Education, Culture, Sports, Science, and Technology of Japan
- Ministry of Education, Culture, Sports, Science and Technology, Japan
Major depressive disorder (MDD) is a common, recurrent mental illness that affects millions of people worldwide. Accumulating evidence suggests that the N-methyl-D-aspartate (NMDA) receptor, a subtype of glutamate receptors, plays an important role in the neurobiology and treatment of this disease. Currently, the non-competitive NMDA receptor antagonist ketamine is considered as one of the most attractive candidate drugs in therapy of treatment-resistant depression. A recent study demonstrated ketamine's rapid antidepressant activity in patients with treatment-resistant MDD and bipolar disorder. The response rate for ketamine ranged from 25% to 85% at 24 hours post-infusion and from 14% to 70% at 72 hours post-infusion, with generally mild adverse effects. Based on the role of the NMDA receptor in depression, a number of therapeutic drugs which interact with this receptor have been developed. In this article, we reviewed recent findings concerning the role of glutamatergic signaling in the neurobiology of MDD and potential, novel therapeutic drugs, such as ketamine, memantine, AZD6765, traxoprodil, MK-0657, GLYX-13, NRX-1047, D-cycloserine, sarcosine, all of which target this system.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据